profit from every $100 of sales.
$0$100
Cytosorbents
$5.80-0.51% today
-59.8% in 1 year
1-year low $3.061-year high $16.74
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cytosorbents sold, what it kept, and what it did with the cash.
Sales went from $29.4 million in 2022 to $37.1 million in 2025, with -$8.20 million of profit last year.
SalesProfit
Cytosorbents vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cytosorbents | No profit yet | ||
 Boston Scientific | 22.4× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.9× · Expensive | ||
 Zimmer Biomet Holdings | 28.8× · Fair price |
AI analysis
An AI analyst reads Cytosorbents's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 29 | 31 | 36 | 37 | |
| 15 | 22 | 25 | 26 | |
| -32 | -32 | -16 | -14 | |
| -30 | -28 | -19 | -4 | |
| -33 | -29 | -21 | -8 | |
| -0.75 | -0.65 | -0.38 | -0.13 | |
| 52.5% | 70.6% | 69.9% | 71.5% | |
| -107.4% | -102.8% | -46.2% | -38.4% | |
| -111.8% | -94.1% | -58.2% | -22.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 63 | 53 | 47 | 44 |
| Cash | 22 | 14 | 3 | 6 |
| Total debt | 18 | 18 | 27 | 29 |
| Total liabilities | 28 | 29 | 36 | 38 |
| 35 | 23 | 11 | 6 | |
| 44 | 45 | 54 | 62 | |
| -46.4% | -56.5% | -43.7% | -13.5% | |
| -92.8% | -124.6% | -186.5% | -138.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -28 | -22 | -14 | -12 | |
| 6 | 1 | 1 | 0 | |
| -35 | -23 | -15 | -13 | |
| Dividends paid | – | – | – | – |
| 0 | – | – | – | |
| 4 | 4 | 4 | 3 |
Valuation
- –
- –
- –
- 13.3×
- 0.5×
- –
- –
- -70.4%
- -44.9%
- 0.0%
Profitability
- 71.5%
- -38.4%
- -22.1%
- -32.7%
- -41.1%
- -48.3%
- -165.1%
- -29.2%
- -55.1%
- 12.0%
Growth
- +8.1%
- –
- +14.8%
- –
- +9.5%
Financial health
- –
- 8.64
- 46.8%
- -11.6×
- 1.09
- 0.81
- 0.92
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 11%of 952
Bottom 8%of 877
Bottom 39%of 871
Bottom 1%of 988
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.08 | -0.06 | −33.3% |
| Mar 25, 2026 | -0.09 | -0.05 | −80.0% |
| Nov 13, 2025 | -0.04 | -0.06 | +33.3% |
| Aug 7, 2025 | -0.05 | -0.07 | +28.6% |
| May 14, 2025 | -0.06 | -0.08 | +25.0% |
| Mar 31, 2025 | -0.03 | -0.07 | +57.1% |
| Nov 7, 2024 | -0.08 | -0.07 | −14.3% |
| Aug 13, 2024 | -0.08 | -0.09 | +11.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
5No pass
Philip Fisher
37No pass
Peter Lynch
14No pass
Joel Greenblatt
0No pass
Charlie Munger
25No pass
Terry Smith
35No pass
Questions about Cytosorbents
Is Cytosorbents a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cytosorbents AI analysis
What does Cytosorbents do?
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. It is in Medical - Devices.
Does Cytosorbents pay a dividend?
No. Cytosorbents does not pay a dividend at the moment.
Is Cytosorbents stock halal?
No. Cytosorbents does not pass our halal screen: its debt is 159% of its market value, at or above the 33% limit. How we check
How has Cytosorbents stock done over the past year?
Down 59.8% over the past twelve months, to $5.80. It traded between $3.06 and $16.74 and is 65.3% below its high.
Who are Cytosorbents's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Cytosorbents's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.